Call Now

Canine CTLA-4 / CD152 Protein (ECD, His Tag)

CTLA4

Catalog Number P70113-D08H
Organism Species Canine
Host Human Cells
Synonyms CTLA4
Molecular Weight The recombinant canine CD152 consists 137 amino acids and predicts a molecular mass of 14.8 kDa.
predicted N Lys 36
SDS-PAGE
Purity > 90 % as determined by SDS-PAGE.
Protein Construction A DNA sequence encoding the canine CD152 (NP_001003106.1) (Met1-Asp161) was expressed with a polyhistidine tag at the C-terminus.
Bio-activity
Research Area Immunology |Adaptive Immunity |Costimulation & Costimulatory Molecule |B7/CD28 Family
Formulation Lyophilized from sterile PBS, pH 7.4.
1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background Cytotoxic T-lymphocyte protein 4, also known as CTLA4 and CD152, is a single-pass type I membrane protein and a member of the immunoglobulin superfamily. It is the second member of the CD28 receptor family. The ligands or counterreceptors for these two proteins are the B7 family members, CD80 (B7-1) and CD86 (B7-2). CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may play an important role in their functions. CD152 or cytotoxic T lymphocyte antigen-4 (CTLA-4) is an essential receptor involved in the negative regulation of T cell activation. Because of its profound inhibitory role, CD152 has been considered a sound susceptible candidate in autoimmunity and a persuasive target for cancer immunotherapy. In particular, recent evidence suggests that CD152 is also important in the homeostasis and function of a population of suppressive cells, termed regulatory T cells (Treg).
Reference
  • Slavik JM, et al. (1999) CD28/CTLA-4 and CD80/CD86 families: signaling and function. Immunol Res. 19(1): 1-24.
  • Holmberg D, et al. (2005) CTLA-4 (CD152) and its involvement in autoimmune disease. Autoimmunity. 38(3): 225-33.
  • Chin LT, et al. (2008) Immune intervention with monoclonal antibodies targeting CD152 (CTLA-4) for autoimmune and malignant diseases. Chang Gung Med J. 31(1): 1-15.